newsfilter.io

Kristen Fortney

Showing 1–4 of 4 transcripts.

  1. Milken Institute59 min

    Longevity Lab: Can You Live to 100? | Global Conference 2024

    Allison Aubrey, James Bethell, Dan Buettner, Peter Diamandis, Kristen Fortney, Lloyd Minor

    A panel of scientists and policymakers discusses converging strategies to achieve longevity escape velocity through the integration of AI-driven biotech, emerging drugs like rapamycin and GLP-1 agonists, and preventative Blue Zone principles that emphasize environmental design over individual willpower. With the XPRIZE Healthspan Competition challenging teams to reverse functional aging within a decade and healthcare systems pivoting from sick care to community-based prevention, the dialogue highlights a transition toward treating aging as a manageable biological process rather than an inevitable decline. While optimistic projections suggest widespread adoption of anti-aging therapies within twenty years, experts caution that true success requires balancing pharmacological interventions with social determinants of health to ensure extended healthspan alongside increased lifespan.

  2. a16z18 min

    a16z Podcast | How to Live Longer and Better

    Kristen Fortney, Jeff Kaditz, David Sinclair, Michael Snyder, Hanne Tidnam, Hannah, Mike Snyder

    Driven by an explosion of biological data and computing power, the longevity sector is transitioning from reactive treatment to proactive precision health, with experts projecting a potential 5 to 15-year increase in human healthspan. Key advancements in tracking molecular signatures and removing senescent cells aim to compress morbidity and save the U.S. healthcare system approximately $3 to $4 trillion by reducing chronic disease prevalence. Despite ongoing debates over data ownership and clinical trial limitations, the convergence of continuous monitoring and pharmacological interventions is establishing a new framework for extending functional life.

  3. a16z29 min

    a16z Podcast | The Science Of Extending Life

    Dr. Thomas Rando, Kristen Fortney, Vijay Pande, Hannah

    Geroscience has transitioned from theoretical concepts to validated interventions like rapamycin and senolytics, which extend lifespan by up to 30% in mammalian models while genomic biomarkers accelerate drug testing from decades to years. Regulatory frameworks are evolving to approve age-delaying therapies such as the FDA's review of the TAME metformin trial, shifting focus from treating specific diseases to preventing aging as a primary risk factor. BioAge and other entities are developing diverse therapeutics to add healthy years to life, aiming to generate massive public cost savings and reshape demographics despite challenges regarding equity and access.

  4. a16z11 min

    Extending Human Lifespan

    Kristen Fortney, Tanya Cushman

    This presentation argues that targeting aging as a root cause of chronic disease offers a superior strategy to treating individual conditions, with projections indicating such interventions could extend average human lifespans to 113 years. Citing breakthroughs in rapamycin, senolytics, and metformin trials alongside genomic insights from exceptional longevity cases, the discussion highlights a shift from skepticism to clinical application where three distinct therapeutic classes are currently advancing toward adding a decade or more of healthy life.